Page 217 - Tata_Chemicals_yearly-reports-2017-18
P. 217

8. (a) Investments in joint ventures



          The Group’s interest in joint ventures are accounted for using the equity method in the consolidated financial statements.

          Following are details of investments in Joint ventures:

          Particulars                                              Country of                       Percentage of
                                                                   Incorporation                ownership Interest
          Indo Maroc Phosphore S.A. (‘IMACID’)                     Morocco                                33.33%

          Natronx Technologies LLC                                 United States of America               33.30%
          JOil (S) Pte. Ltd. (‘JOil’)                              Singapore                              33.78%
          The Block Salt Company Ltd.                              United Kingdom                         50.00%    Integrated Report

          The Group had no contingent liabilities or capital commitments relating to its interest in joint ventures as at 31 March, 2018 and 2017. The joint
          ventures have no other contingent liabilities or capital commitments as at 31 March, 2018 and 2017.

          Carrying amount of investment in joint ventures
                                                                                                         ` in crore
          Particulars                                                                       As at          As at
                                                                                   31 March, 2018  31 March, 2017
          Indo Maroc Phosphore S.A.                                                        351.42          293.24
          Natronx Technologies LLC*                                                             -              -
          JOil (S) Pte. Ltd.*                                                                   -              -
          The Block Salt Company Ltd.                                                        2.53            2.22   Statutory Reports
          Margin elimination on stock                                                       (1.23)          (3.25)
          Total                                                                            352.72         292.21

          *The Group has impaired 100% investment during the year ended 31 March, 2015.
                                                                                                         ` in crore
          Summary of movement of investment in joint ventures                          Year ended     Year ended
                                                                                   31 March, 2018  31 March, 2017
          Opening carrying value as at 1 April                              A              292.21          311.55
          Add/(Less):
          Additional Investment                                             B                1.91           13.14
          Add: Share of profit of joint ventures                                                                    Financial Statements

          Group’s share of profit for the year                                               47.00           12.75
          Margin elimination on stock                                                        2.23            2.87
                                                                            C               49.23          15.62
          Adjusted against provision made earlier for onerous contract      D                   -           (9.46)
          Dividend received for the year                                    E               (9.82)         (20.33)
          Exchange fluctuations                                              F               19.19          (18.31)
          Closing carrying value as at 31 March                            A to F          352.72         292.21






                                                                              Consolidated Financial Statements 215
   212   213   214   215   216   217   218   219   220   221   222